Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2021
Lipocine and Clarus enter global settlement agreement
Lipocine and Clarus Therapeutics entered into a global settlement agreement to resolve outstanding claims in their intellectual-property litigation and an interference proceeding between the companies.
2021
Lipocine reports second-quarter 2021 financial results
Lipocine announced financial results for the second quarter ended June 30, 2021, reporting a net loss of $6.8 million, or $0.08 per diluted share.
2021
USPTO declares patent interference between Lipocine and Clarus applications
Lipocine announced that the USPTO's Patent Trial and Appeal Board declared a patent interference between a Lipocine-owned U.S. patent application and a Clarus-owned U.S. patent application, and that the USPTO withdrew the Clarus application from issue in preparation.
2020
Judge postpones Lipocine–Clarus patent trial
Judge William C. Bryson of the U.S. District Court of Delaware postponed the jury trial scheduled for February 8, 2021, in Lipocine's patent litigation against Clarus Therapeutics because of the ongoing effects of the COVID-19 pandemic. Lipocine alleges that Clarus's JATENZO product infringes its U.S. patents; the trial is to be rescheduled when jury trials resume in the district.